Back to results
US 12,383,631 B2Granted
Immune antigen specific IL-18 immunocytokines and uses thereof
AssigneeBright Peak Therapeutics AG
InventorsVijaya Raghavan Pattabiraman, Bertolt Kreft, Jean-Philippe Carralot, Arnaud Goepfert, Kea Martin, Andrew Chi
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to modified immunocytokine compositions comprising antibodies or antigen binding fragments specific for immune cell antigens and IL-18 polypeptides. Also provided herein are methods of treatment with and methods of manufacture of immunocytokine compositions.
Claims20
An immunocytokine composition, comprising:
- an IL-18 polypeptide, wherein the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO:
- 30;
- and
- an antibody or an antigen binding fragment thereof specific for an immune cell associated antigen;
- and
- a linker, wherein the linker comprises:
- a first point of attachment to the IL-18 polypeptide;
- and
- a second point of attachment to the antibody or antigen binding fragment thereof.
6 more elements
An immunocytokine composition, comprising:
- an IL-18 polypeptide having the amino acid sequence set forth in SEQ ID NO:
- 30;
- an antibody or an antigen binding fragment thereof comprising an Fc region and having a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO:
- 376 and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:
- 377;
- and
- a linker, wherein the linker comprises:
- a first point of attachment to residue C68 of the IL-18 polypeptide;
- and
- a second point of attachment to the antibody or antigen binding fragment thereof at Lys 248 of the Fc region, wherein amino acid residue position number is based on EU numbering.
7 more elements
An immunocytokine composition, comprising:
- an IL-18 polypeptide having the amino acid sequence set forth in SEQ ID NO:
- 30;
- an antibody or an antigen binding fragment thereof specific for programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1);
- and
- a linker, wherein the linker comprises:
- a first point of attachment to residue C68 the IL-18 polypeptide;
- and
- a second point of attachment to the antibody or antigen binding fragment thereof.
5 more elements
Dependencies are inferred from the claim text.